Amicus Therapeutics is a public American biopharmaceutical company founded on February 4th, 2002. The company has its headquarters in Cranbury, New Jersey. Amicus Therapeutics is a global biotechnology company at the forefront of improved therapies to treat a variety of desolating rare and orphan diseases (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/). This kind of diseases includes; Epidermolysis Bullosa (EB,) Pompe diseases as well as Lysosomal Storage Disorders and the Fabry disease.
The amicus therapeutics company has an exclusive set of programs in technologies and medicines in development for people living with these kinds of rare orphan diseases. The company has developed a platform Chaperone-Advanced Replacement Therapy that aims at enzyme replacement therapy (ETR) products for Fabry disease, Pompe disease, and other lysosomal storage disorders. The company is also working to develop a biologics program ATB200/AT2221 which will uniquely be administered in the treatment of Pompe disease.
Amicus Therapeutics Company uses advanced technology, and it has seen it at the forefront of developing therapies in addressing and meeting the needs of the rare and orphan diseases (SeekingAlpha). Apart from developing a pipeline towards the treatment of these rare diseases, amicus professionals act as a bridge between the patients, their families and the resources also offer access to support and services across their disease experience.
The amicus therapeutics finally has its goal to make a meaningful difference in the lives of these patients. It has greatly contributed to the development of the first Fabry disease medicine Galafold through EMA and is working to obtain approval for further studies. Also, it is expecting a pivotal three phrase trial readouts in epidermolysis bullosa (ER).
Osteo Relief Institute is a privately owned firm that works in close collaboration with highly experienced staff to offer services such as communication and care to patients. The firm is highly equipped with high-tech equipment to provide its clients with customized pain relief solutions. The technology adopted by at Osteo Relief Institute is legally certified and approved by FDA. The firm is peculiar and competent in meeting all the arthritis management needs of patients.
Osteo Relief Institute is resourceful to the residents of New Jersey who are struggling with Osteoarthritis. Osteo Relief Institute was established in 2012 in New Jersey. This firm is reputable for its professionalism in advocating for positive lifestyle changes. Further, the company offers extensive and affordable medical pain relief services to its clients.
Arthritis is one of the most common medical conditions that is managed at Osteo Relief Institute (HealthGrades). According to stats, Arthritis affects an excess of 50 million adults across the United States of America. Osteo Relief Institute understands different forms in which arthritis manifests itself. Research further revealed that the condition is more prevalent in women. Arthritis is one of the major causes of disability in the United States of America.
Arthritis is a very common condition that presents itself in different forms. It is interesting to note that many people think of arthritis as a single disease. On the contrary, arthritis is a joint disease that comprises of more than 100 different conditions and is more prevalent as one age. Osteoarthritis, also called degenerative joint disease, is the common type of arthritis that degenerates the cartilages, particularly in joints.
Osteoarthritis exposes the bone to friction resulting in swelling, stiffness, and pain. At chronic stages, joints lose their strength. The condition has no cure; however, Osteo Relief Institute offers several treatment options to help in pain managing. Excess weight, age, previous injury, and family history are among the risk factors associated with osteoarthritis. Osteo Relief Institute manages Osteoarthritis through medical intervention, daily routine, and exercise.